|
1
|
Busygina V and Bale AE: Multiple endocrine
neoplasia type 1 (MEN1) as a cancer predisposition syndrome: clues
into the mechanisms of MEN1-related carcinogenesis. Yale J Biol
Med. 79:105–114. 2006.
|
|
2
|
Chandrasekharappa SC, Guru SC, Manickam P,
et al: Positional cloning of the gene for multiple endocrine
neoplasia-type 1. Science. 276:404–407. 1997.
|
|
3
|
Larsson C, Skogseid B, Oberg K, Nakamura Y
and Nordenskjöld M: Multiple endocrine neoplasia type 1 gene maps
to chromosome 11 and is lost in insulinoma. Nature. 332:85–87.
1988.
|
|
4
|
Thakker RV, Bouloux P, Wooding C, et al:
Association of parathyroid tumors in multiple endocrine neoplasia
type 1 with loss of alleles on chromosome 11. N Engl J Med.
321:218–224. 1989.
|
|
5
|
Farnebo F, Teh BT, Kytölä S, et al:
Alterations of the MEN1 gene in sporadic parathyroid tumors. J Clin
Endocrinol Metab. 83:2627–2630. 1998.
|
|
6
|
Brandi ML, Gagel RF, Angeli A, et al:
Guidelines for diagnosis and therapy of MEN type 1 and type 2. J
Clin Endocrinol Metab. 86:5658–5671. 2001.
|
|
7
|
Romei C, Pardi E, Cetani F and Elisei R:
Genetic and clinical features of multiple endocrine neoplasia types
1 and 2. J Oncol. 2012:7050362012.
|
|
8
|
Morelli A, Falchetti A, Martineti V, et
al: MEN1 gene mutation analysis in Italian patients with multiple
endocrine neoplasia type 1. Eur J Endocrinol. 142:131–137.
2000.
|
|
9
|
Chung YJ, Kim HH, Kim HJ, et al: RET
proto-oncogene mutations are restricted to codon 634 and 618 in
Korean families with multiple endocrine neoplasia 2A. Thyroid.
14:813–818. 2004.
|
|
10
|
Kim BY, Lee DG, Lee KR, et al:
Identification of BRCA1 and BRCA2 mutations from Korean breast
cancer patients using denaturing HPLC. Biochem Biophys Res Commun.
349:604–610. 2006.
|
|
11
|
Giraud S, Zhang CX, Serova-Sinilnikova O,
et al: Germ-line mutation analysis in patients with multiple
endocrine neoplasia type 1 and related disorders. Am J Hum Genet.
63:455–467. 1998.
|
|
12
|
Honda M, Tsukada T, Horiuchi T, et al:
Primary hyperparathyroidism associated with aldosterone-producing
adrenocortical adenoma and breast cancer: Relation to MEN1 gene.
Intern Med. 43:310–314. 2004.
|
|
13
|
Inic ZM, Inic M, Dodic R, Pupic G and
Damjanovic S: Breast cancer in a patient with multiple endocrine
neoplasia type 1 (MEN1): A case report and review of the
literature. J Clin Oncol. 30(suppl): abstract 221136. 2012.
|
|
14
|
Papi L, Palli D, Masi L, et al: Germline
mutations in MEN1 and BRCA1 genes in a woman with familial multiple
endocrine neoplasia type 1 and inherited breast-ovarian cancer
syndromes: a case report. Cancer Genet Cytogenet. 195:75–79.
2009.
|
|
15
|
Ghataorhe P, Kurian AW, Pickart A, et al:
A carrier or both MEN1 and BRCA2 mutations: case report and review
of the literature. Cancer Genet Cytogenet. 179:89–92. 2007.
|
|
16
|
Chandrasekharappa SC and Teh BT:
Functional studies of the MEN1 gene. Functional studies of the MEN1
gene. J Intern Med. 253:606–615. 2003.
|
|
17
|
Knudson AG Jr: Mutation and cancer:
statistical study of retinoblastoma. Proc Natl Acad Sci USA.
68:820–823. 1971.
|
|
18
|
Lemos MC and Thakker RV: Multiple
endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations
reported in the first decade following identification of the gene.
Hum Mutat. 29:22–32. 2008.
|
|
19
|
Kouvaraki MA, Lee JE, Shapiro SE, et al:
Genotype-phenotype analysis in multiple endocrine neoplasia type 1.
Arch Surg. 137:641–647. 2002.
|
|
20
|
Lips CJ, Dreijerink KM and Höppener JW:
Variable clinical expression in patients with a germline MEN1
disease gene mutation: clues to a genotype-phenotype correlation.
Clinics (Sao Paolo). 67(Suppl 1): 49–56. 2012.
|
|
21
|
Ellard S, Hattersley AT, Brewer CM and
Vaidya B: Detection of an MEN1 gene mutation depends on clinical
features and supports current referral criteria for diagnostic
molecular genetic testing. Clin Endocrinol (Oxf). 62:169–175.
2005.
|
|
22
|
Klein RD, Salih S, Bessoni J and Bale AE:
Clinical testing for multiple endocrine neoplasia type 1 in a DNA
diagnostic laboratory. Genet Med. 7:131–138. 2005.
|
|
23
|
Park JH, Kim IJ, Kang HC, et al: Germline
mutations of the MEN1 gene in Korean families with multiple
endocrine neoplasia type 1 (MEN1) or MEN1-related disorders. Clin
Genet. 64:48–53. 2003.
|
|
24
|
Agarwal SK, Guru SC, Heppner C, et al:
Menin interacts with the AP1 transcription factor JunD and
represses JunD-activated transcription. Cell. 96:143–152. 1999.
|
|
25
|
Heppner C, Bilimoria KY, Agarwal SK, et
al: The tumor suppressor protein menin interacts with NF-kappaB
proteins and inhibits NF-kappaB-mediated transactivation. Oncogene.
20:4917–4925. 2001.
|
|
26
|
Kim H, Lee JE, Cho EJ, Liu JO and Youn HD:
Menin, a tumor suppressor, represses JunD-mediated transcriptional
activity by association with an mSin3A-histone deacetylase complex.
Cancer Res. 63:6135–6139. 2003.
|
|
27
|
Itakura Y, Sakurai A, Katai M, et al:
Enhanced sensitivity to alkylating agent in lymphocytes from
patients with multiple endocrine neoplasia type 1. Biomed
Pharmacother. 54(Suppl 1): 187s–190s. 2000.
|
|
28
|
Jin S, Mao H, Schnepp RW, et al: Menin
associates with FANCD2, a protein involved in repair of DNA damage.
Cancer Res. 63:4204–4010. 2003.
|
|
29
|
Binz SK, Sheehan AM and Wold MS:
Replication protein A phosphorylation and the cellular response to
DNA damage. DNA Repair (Amst). 3:1015–1024. 2004.
|
|
30
|
Kim YS, Burns AL, Goldsmith PK, et al:
Stable overexpression of MEN1 suppresses tumorigenicity of RAS.
Oncogene. 18:5936–5942. 1999.
|
|
31
|
Dreijerink KM, Mulder KW, Winkler GS,
Höppener JW, Lips CJ and Timmers HT: Menin links estrogen receptor
activation to histone H3K4 trimethylation. Cancer Res.
66:4929–4935. 2006.
|
|
32
|
Prest SJ, May FE and Westley BR: The
estrogen-regulated protein, TFF1, stimulates migration of human
breast cancer cells. FASEB J. 16:592–594. 2002.
|
|
33
|
Corte MD, Tamargo F, Alvarez A, et al:
Cytosolic levels of TFF1/pS2 in breast cancer: Their relationship
to clinical-pathological parameters and their prognostic
significance. Breast Cancer Res Treat. 96:63–72. 2006.
|
|
34
|
Bauche E, Etique N, Alpy F, et al:
Deficiency in trefoil factor 1 (TFF1) increases tumorigenicity of
human breast cancer cells and mammary tumor development in
TFF1-knockout mice. Oncogene. 30:3261–3273. 2011.
|
|
35
|
Amiry N, Kong X, Muniraj N, et al: Trefoil
factor-1 (TFF1) enhances oncogenicity of mammary carcinoma cells.
Endocrinology. 150:4473–4483. 2009.
|
|
36
|
Hähnel E, Robbins P and Hähnel R:
Expression of the pS2 gene in normal breast tissue. Breast Cancer
Res Treat. 28:295–297. 1993.
|
|
37
|
Poulsom R, Hanby AM, Lalani EN, Hauser F,
Hoffmann W and Stamp GW: Intestinal trefoil factor (TFF 3) and pS2
(TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are
co-expressed in normal, hyperplastic, and neoplastic human breast
epithelium. J Pathol. 183:30–38. 1997.
|
